LY294002

Catalog No.S1105 Synonyms: SF 1101, NSC 697286

LY294002 Chemical Structure

Molecular Weight(MW): 307.34

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 73 Publications

15 Customer Reviews

  • Type I IFNs induce ISG expression in a serine phosphorylation-independent manner. Cells were treated with kinase inhibitors (SB203580, rottlerin, Ly294002, PD98059, and SP600125) before stimulation with IFN-a and IFN-b for 6 hours. Cell lysates were used in western blotting and probed for serine phosphorylation.The relative amounts of pSTAT1 S727 in (up-graph) were quantied and normalized to an untreated control (below-graph).

    Hepatology 2014 59(4), 1262-72. LY294002 purchased from Selleck.

    different signal-inhibitory profile by applying 120 nmol/L BGT226, 20 μmol/L LY294002, or 100 nmol/L rapamycin in FaDu cells.

    Clin Cancer Res 2011 17, 7116-7126. LY294002 purchased from Selleck.

  • Stimulation response of p37d-expressing cells. (c) Western blot of 5 min serum stimulated HEK-293 cells stably expressing p37d, p110d or control, with the presence of inhibitors as indicated at the top.

    Oncogene 2012 31, 3277–3286. LY294002 purchased from Selleck.

    PTEN transfection or inhibition of the PI3K-AKT and IGF-1R signaling pathways increases the trastuzumab sensitivity of NCI-N87/TR cells. After treating the cells with a PI3K inhibitor (LY294002), the expression of AKT and P-AKT proteins was assessed by Western blotting. Tubulin expression indicated equal loading. All gels run under the same experimental conditions and the experiments were repeated 3 times. The representative images were cropped and shown. Control: cells without any treatment.

    Sci Rep 2015 5, 11634. LY294002 purchased from Selleck.

  • SCC61 or Detroit 562 xenografted tumors respond to treatment by PI3K inhibitor, LY294002 alone, or in combination with gefitinib. % tumor growth is shown. By two-way ANOVA, the effect of treatment and time is considered significant;

    Mol Oncol 2013 7, 359-68. LY294002 purchased from Selleck.

    Inhibition of EGFR and PI3K/AKT pathway has additive effects in SCCHN cell lines with constitutively active PIK3CA mutations, while removing negative regulation of PI3K/AKT pathway increases resistance in sensitive SCCHN cell line. A, results from MTT assays on cells treated with PI3K inhibitor, LY294002, and gefitinib.

    Mol Oncol 2013 7, 359-68. LY294002 purchased from Selleck.

  • Lyn-PI3K-BTK signaling is required for the inhibitory effect of anti-CD180 on the activation of IFN-α signaling. (a and b) Isolated murine splenic B220+ B cells were pretreated with dasatinib (5 μM), a Lyn inhibitor; LY294002 (5 μM), a PI3K inhibitor; ibturinib (1 μM), a BTK inhibitor; enzastaurin (1 μM), a PKC β inhibitor; U0126 (3 μM), an ERK inhibitor; SP600126 (2 μM), a JNK inhibitor or SB20358 (1 μM), a p38 inhibitor for 1 h, followed by stimulation with anti-CD180 antibody (0.2 μg/mL) or mouse IFN-α (1000 U/mL) for 4 h. qPCR analysis of the expression of IFIT1 (a) and MX1 (b). (c) Isolated murine splenic B220+ B cells were pretreated with dasatinib (5 μM), LY294002 (5 μM), and ibturinib (1 μM) for 1 h, followed by stimulation with anti-CD180 antibody (0.2 μg mL−1) or mouse IFN-α (1000 U mL−1) for 40 min. Western blot analysis of the phosphorylation level of STAT-2. The data shown represent the mean values of three independent experiments, and the error bars represent the SEM. *p < 0.05, **p < 0.01, ***p < 0.001, as determined by ANOVA; ns denotes p > 0.05.

    Cell Mol Immunol, 2017, 14(2):192-202. LY294002 purchased from Selleck.

    The effects of GLP-1R siRNA and LY294002 on neurological score at 24 hours after subarachnoid hemorrhage (SAH) in Ex-4 treated rats.

    Neuropharmacology, 2018, 128:142-151. LY294002 purchased from Selleck.

  • Immunofluorescence and flow cytometric analyses of the translocation of ABCG2 in MCF-7 FLV1000 cells before and after treatment with the PI3K inhibitor LY294002. Confocal microscopy of MCF-7 FLV1000 cells after a 16-h treatment with 2 uM or 4 uM of LY294002 was performed as described in Figure.

    Br J Pharmacol 2013 70(5), 1137-51. LY294002 purchased from Selleck.

    IGF1 increases apical fibronectin in late stage blastocysts. Representative confocal images of blastocysts stained for fibronectin (Green) and DAPI (Blue). Day 5 blastocysts were cultured in SS medium for 24 (A and B), 48 (C and D) or 72 h (E-H) in the absence (A, C and E) or presence (B, D and F) of 10 ng/ml IGF1 or in the presence of a PI3 Kinase inhibitor (5 uM LY294002 + 10 ng/ml IGF1) (G) or in the presence of 10 ng/ml IGF1, attached to a coverslip (H). Scale bars represent 20 mm. Red line indicates location of coverslip. Arrow indicates location of the inner cell mass (ICM). The following total number of blastocysts were analysed, from at least 3 experimental repeats in each treatment; 24 in the SS group (24 h), 21 in SS plus IGF1 (24 h), 26 in SS (48 h), 30 in SS plus IGF1 (48 h), 40 in SS (72 h), 59 in SS plus IGF1 (72 h), 13 in SS plus IGF1 + LY294002 (48 h) and 15 blastocysts were analysed that were attached to a coverslip (72 h).

    Hum Reprod 2015 30(2), 284-98. LY294002 purchased from Selleck.

  • Inhibition of PI3K, ERK and mTOR prevents the activation of S6K1 and S6 induced by suppression of PKD1 activity. A549 cells were incubated in the absence (-) or presence of either 5 uM Kb or 5 uM Kb and 20 uM LY294002 or 5 uM Kb and 10 uM BKM120 (as indicated) for 1 h prior to stimulation of cells with 50 nM PMA for 30 min and 1 h.

    Int J Biochem Cell Biol 2015 60, 34-42. LY294002 purchased from Selleck.

    Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823(5), 987-96. LY294002 purchased from Selleck.

  • Comparative effects of wortmannin and LY294002 on ADRP and β -casein synthesis. Con fluent HC11 cells were treated according to the standard procedure in the absence or presence of 4 ng/ml EGF either with or without 100 nM wortmannin or 50μM LY294002. Cellular proteins were analyzed by SDS-PAGE and immunoblot successively probed with anti-ADRP, anti-β-casein, anti-β -actin antibodies and their respective HRP-conjugated secondary antibodies. ECL signals were quantified by densitometry and normalized to β-actin. Each experimental condition was performed in triplicate. Percentages of inhibition for both inhibitor and hormonal treatments are indicated in the text.

    Biochim Biophys Acta 2012 1823(5), 987-96. LY294002 purchased from Selleck.

    We treated all of drugs in T47D which has a PI3KCA H1044R mutation with the concentration shown below for 1 hour and performed western blot analysis using antibodies to phospho-AKT(SERINE 472), and total AKT.

     

     

    2010 Saraswati Sukumar of Johns Hopkins University School of Medicine. LY294002 purchased from Selleck.

  • T47Dcells were pretreated with 100 ng/ml EGF for 20 min and then treated with the indicated concentrations of LY294002 for 24 hours.

     

     

    2010 Dr. Zhang of Tianjin Medical University. LY294002 purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
Targets
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
DNA-PK [6]
(Cell-free)
DNA-PK [6]
(Cell-free assay)
0.5 μM 0.57 μM 0.97 μM 1.4 μM 1.4 μM
In vitro

LY294002 is not exclusively selective for the PI3Ks, and could in fact act on other lipid kinases and additional apparently unrelated proteins. LY294002 is shown to inhibit not only mTOR and DNA-PK, but also other protein kinases, such as CK2 (casein kinase 2) and Pim-1[5]. LY294002 inactivates Akt/PKB, consequently inhibiting cell proliferation and inducing apoptosis. LY294002 demonstrates a remarkable growth-inhibitory and apoptosis-inducing effect in these colon cancer cell lines, with decreased expression of phosphorylated Akt (Ser473). [2]LY294002 induces marked nuclear pyknosis and diminished cytoplasmic volume in the tumor cells. Thus, LY294002 markedly inhibits ovarian cancer cell proliferation in vitro. LY294002 induces specific G1 arrest in cell growth, leading to almost complete inhibition of melanoma cell proliferation and partial inhibition of MG-63 (osteosarcoma cell line) proliferation. The effect of LY294002 on cell cycle progression may provide insights into a possible link between the PI3K activation pathway and cancer cell cycle regulation. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDA-MB-231 cells NHe2TYdE\WyuIHnueoF{cW:wIHHzd4F6 NIPSV4MzPCCq NWTSbIR{UW6qaXLpeIlwdiCxZjDldIl1cGWuaXHsJIdzd3e2aDDmZYN1d3JvaX7keYNm\CClZXzsJI1q\3KjdHnvckBw\iCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJJBz\S2rbnP1ZoF1\WRiZn;yJFI1KGi{czDifUBk\WyuIHnueoF{cW:wIHHzd4F6NCCLQ{WwQVAvOzhizszNMi=> M{T2UFIzQDB2MUC4
Sf21 cells NE\4dI5HfW6ldHnvckBie3OjeR?= NIDhOY5KdmirYnn0bY9vKG:oIH3veZNmKHerbHSgeJlx\SCSSUPLZYxxcGFiZYjwdoV{e2WmIHnuJHNnOjFiY3XscJMh[29vZYjwdoV{e2mwZzDOMZRmem2rbnHsJGhqey22YXfn[YQhcHWvYX6gdFg2[SC3c3nu[{BNNWGucHjhMZBpd3OyaHH0bYR6dGmwb4PpeI9tKHO3YoP0doF1\SCkeTDUUGMh[mG|ZXSgdIhwe3Cqb4KgbY1i\2mwZzygTWM2OD1yLkWg{txO MYGyNlUzODZ|MB?=
Sf21 cells MUPGeY5kfGmxbjDhd5NigQ>? M4XFSmlvcGmkaYTpc44hd2ZibX;1d4UhemWlb33ibY5idnRiUFmzT4FteGijIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2ey2rbn\lZ5Rm\CCVZkKxJINmdGy|LDDJR|UxRTBwNTFOwG0v MX2xPVc1QDJ4OR?=
Sf9 cells NIXMWI5HdHWxcnXzZ4VvfCCyb3zhdol7[XSrb36gZZN{[Xl? NHK1XXlKdmirYnn0bY9vKG:oIHj1cYFvKFCLM1vhcJBp[SCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIJ6KG[udX;y[ZNk\W62IIDvcIFzcXqjdHnvckBie3OjeTygTWM2OD1yLkW1JO69VS5? NGr1PYUzOTF{MU[zNS=>
THP1 cells NEflVolHfW6ldHnvckBie3OjeR?= NGfjVo1KdmirYnn0bY9vKG:oIGPDSlEucW6mdXPl[EBRU0JxQXv0JJBpd3OyaH;yfYxifGmxbjDpckBVUFBzIHPlcIx{NCCLQ{WwQVEvODFizszNMi=> NFj1NmYyPjd6OUe0Ni=>
human PC3 cells M4PLR2Z2dmO2aX;uJIF{e2G7 MV:zNEBucW5? NWDkTGRRUW6qaXLpeIlwdiCxZjDQTVNMKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBCU1RicHjvd5Bpd3K7bHH0bY9vKGG2IIPldolv\SB2N{OgZYZ1\XJiM{CgcYlveyCkeTDFUGlUSSxiSVO1NF0yNjQQvF2u NEW2fZQzOzRzMECwOS=>
HeLa (human carcinoma) cells. MWDGeY5kfGmxbjDhd5NigQ>? NH3FV3NKdiC4aYTyc{BqdmirYnn0bY9vKG:oIFTORU1l\XCnbnTlcpQheHKxdHXpckBscW6jc3WoSG5CNVCNKTDmdo9uKEinTHGgLIh2dWGwIHPhdoNqdm:vYTmgZ4VtdHNuIFnDOVA:OS52IN88UU4> MYmxOVY2QDh5MB?=
THP1 cells NFvwdXJHfW6ldHnvckBie3OjeR?= MmDSTY5pcWKrdHnvckBw\iCPQ2CxMYlv\HWlZXSgVGtDN0GtdDDwbI9{eGixconsZZRqd25iaX6gWGhROSClZXzsd{whUUN3ME2xMlY2KM7:TT6= M{mwcFE3Pzh7N{Sy
HeLa cells NH\KPW1HfW6ldHnvckBie3OjeR?= MXLJcohq[mm2aX;uJI9nKG2WT2KgdJJwfGWrbjDpd49t[XSnZDDmdo9uKEinTHGgZ4VtdHNuIFnDOVA:Oi53IN88UU4> M4j4VlE2PjV6OEew
human MCF7 cells NHnERVBEgXSxdH;4bYPDqGG|c3H5 NEf3WJREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGmwIIDy[ZNmdmOnIH;mJFIxKM7:TTDjbIxwem:zdXnu[UBjgSCVUlKgZZN{[XluIFfJOVA:Oi54MzFOwG0v M4rBNVE5PjlzOEm0
HeLa cells NWS5U5hPTnWwY4Tpc44h[XO|YYm= NEfsU|BKdmirYnn0bY9vKG:oIFHYMVc2ODNiYnnu[Ilv\yC2bzDy[YNwdWKrbnHueEBRdGt|IHX4dJJme3OnZDDpckBJ\UyjIHPlcIx{KGK7IGfld5Rmem5iYnzveEwhUUN3PUOg{txONg>? NIn2[3gyPzF|NUK0PC=>
human MCF7 cells NICzZldEgXSxdH;4bYPDqGG|c3H5 MlHCR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BqdiCycnXz[Y5k\SCxZjCxNEB2VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZktKEeLNUC9N{4xQCEQvF2u M1HjNVE5PjlzOEm0
human MCF7 cells Ml:1R5l1d3SxeHnjxsBie3OjeR?= MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m9N{4yPiEQvF2u NXH0WGdxOTh4OUG4PVQ>
human MDA-MB-231 cells NEfiNYNEgXSxdH;4bYPDqGG|c3H5 NIL6cHpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEKwJO69VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZktKEeLPUOuN|Ih|ryPLh?= MmrvNVg3QTF6OUS=
human MDA-MB-231 cells MljFR5l1d3SxeHnjxsBie3OjeR?= NVjje3BCS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BqdiCycnXz[Y5k\SCxZjCxNEB2VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZktKEeLNUC9OE4{PSEQvF2u NFLzd3cyQDZ7MUi5OC=>
human MDA-MB-468 cells MY\DfZRwfG:6aXRCpIF{e2G7 M13YRmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20Olgh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiMkCgeW0h[2iub4LvdZVqdmViYomgV3JDKGG|c3H589yNKEmFNUC9OE44PiEQvF2u MVexPFY6OTh7NB?=
human HCT116 cells NHvKSohIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M33xdFQ5KGh? M4fpS2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhEXDFzNjDj[YxteyCxdnXy[ZhxemW|c3nu[{BRUTONYXzwbIEhUDFyNEfSJI12fGGwdDDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTVwMzFOwG0> M1\2OlIzOjF{N{Kx
human HCT116 cells NHS5fpRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWjKTWR2PDhiaB?= MnjwS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9OU45KM7:TT6= MXeyNlIyOjd{MR?=
HeLa cells NWXNb2g{SmmwZHnu[{Bi\m[rbnn0fUBie3OjeR?= MWLCbY5lcW6pIHHm[olvcXS7IH\vdkBRUTNva3nuZZNmKGm|b3zheIVlKG[{b32gTIVN[SClZXzsd{whU2l;NjFOwG0> Mn60NVU3PTh6N{C=
human HCT116 cells M2fpeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1fFXFQ5KGh? M33Z[Gdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhEXDFzNjDj[YxteyCxdnXy[ZhxemW|c3nu[{BRUTONYXzwbIEh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME22Mlch|ryPLh?= NUTXVY1IOjJ{MUK3NlE>
MDA-MB-231 cells NUPpOXJwS3m2b4TvfIlkyqCjc4PhfS=> M1rTR2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZpkhW1KEIHHzd4F6NCCJSUWwQVYvPzFizszNMi=> MV2xPFY6OTh7NB?=
Sf9 cells MVnGeY5kfGmxbjDhd5NigQ>? MWnJcohq[mm2aX;uJI9nKEONMjDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{NCCLQ{WwQVYvQSEQvF2u MXmxPFMzOTdzNh?=
human U87MG cells M3[1SGZ2dmO2aX;uJIF{e2G7 MnjPTY5pcWKrdHnvckBw\iCJU1uzMYJmfGFiaX6gbJVu[W5iVUi3UWch[2WubIOgZpkhTUyLU1GsJGlEPTB;OD6xJO69VS5? NViyUIMyOTh|NEW2NFk>
human MDA-MB-468 cells M4T1bGN6fG:2b4jpZ:Kh[XO|YYm= M3G4RmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20Olgh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiMUCgeW0h[2iub4LvdZVqdmViYomgV3JDKGG|c3H5MEBIUTVyPUiuNkDPxE1w MXGxPFY6OTh7NB?=
human A375 cells MlLsVJJwdGmoZYLheIlwdiCjc4PhfS=> MUO0OkBp MnzTRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDM{e1JINmdGy|IHHmeIVzKDR4IHjyd{whUUN3ME24MlQh|ryPLh?= NUTRW|lsOTdyNEmyOFg>
human A375 cells MmnxVJJwdGmoZYLheIlwdiCjc4PhfS=> MV7Jcohq[mm2aX;uJI9nKHOncoXtMYlv\HWlZXSgdJJwdGmoZYLheIlwdiCxZjDoeY1idiCDM{e1JINmdGy|LDDJR|UxRThwNDFOwG0v M3vidFE4PjBzN{O5
human HL60 cells NYPhSZdzS3m2b4TvfIlkyqCjc4PhfS=> MmDKO|IhcA>? M{H4O2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhNPjBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME25Mlk1KM7:TT6= MnPJNlI1QDB6NUG=
mouse Raw264 macrophage M2fkbmZ2dmO2aX;uJIF{e2G7 NHPk[W1KdmirYnn0bY9vKG:oIFO1ZU1u\WSrYYTl[EBRU0JxQXv0JJBpd3OyaH;yfYxifGmxbjDpckBud3W|ZTDSZZczPjRibXHjdo9xcGGpZTygTWM2OD1zMDFOwG0v MV[xOlc5QTd2Mh?=
Sf9 cells MlXLSpVv[3Srb36gZZN{[Xl? M2O4PGlvcGmkaYTpc44hd2ZiSHnzMZRi\2enZDDic5ZqdmViUFmzT{BmgHC{ZYPz[YQhcW5iU3[5JINmdGy|LDDJR|UxRTFyIN88UU4> NF:xUFYyODl7OEO1NS=>
human MDA-MB-468 cells NUXuT5lzS3m2b4TvfIlkyqCjc4PhfS=> NGfidmhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFY5KGOnbHzzJIJ6KFOUQjDhd5NigSxiSVO1NF0yOC52IN88UU4> M3rQPVE5PjlzOEm0
human PC3 cell M3zwNXBzd2yrZnXyZZRqd25iYYPzZZk> MX23NkBp NXnTR|VwUW6qaXLpeIlwdiCxZjDoeY1idiCSQ{OgZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDzdIVkfHKxcHjveI9u\XS{aXOgZY5idHm|aYOsJGlEPTB;MUKuNUDPxE1w MojYNlM1OTByMEW=
human HL60 cells NHfHT5ZRem:uaX\ldoF1cW:wIHHzd4F6 MlTsO|IhcA>? M1TTOmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHid49z[mGwY3WgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1zOD60N{DPxE1w M325dlI2Pjl|N{i3
human BT474 cell M{j0cXBzd2yrZnXyZZRqd25iYYPzZZk> M4LNU|czKGh? M2DJXGlvcGmkaYTpc44hd2ZiaIXtZY4hSlR2N{SgZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDzdIVkfHKxcHjveI9u\XS{aXOgZY5idHm|aYRvwKwhUUN3ME2yNE44KM7:TT6= NVfjfZN[OjN2MUCwNFU>
THP1 cells Mlz1SpVv[3Srb36gZZN{[Xl? M3fZU2lvcGmkaYTpc44hd2ZiTVPQNU1qdmS3Y3XkJINp\W2xdHH4bZMhd2ZiVFjQNUBk\WyuczygTWM2OD1|NzFOwG0v MlfFNVY4QDl5NEK=
human 184B5 cells NULwW3lUS3m2b4TvfIlkyqCjc4PhfS=> NFTEOlZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckAyQDSENTDj[YxteyCkeTDTVmIh[XO|YYmsJGdKPTB;M{muN|ch|ryPLh?= M{LXPVE5PjlzOEm0
human KB cells MUnDfZRwfG:6aXRCpIF{e2G7 M4[zOVczKGh? MV;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTR2Lke2JO69VS5? M1:2clIyQTR3MkWw
mouse RAW264.7 cells NGnjfWVHfW6ldHnvckBie3OjeR?= MlTnNlUh|ryP MV6yNEBp MWrJcohq[mm2aX;uJI9nKFCLM1uvRWtVKGmwIH3veZNmKFKDV{K2OE44KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gUHBUNWmwZIXj[YQhcU6RUzDwdo91\WmwIHX4dJJme3Orb36gZZQhOjVizszNJIFnfGW{IEKwJIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> MXKyOFI6QTZzNh?=
human A2780 cells NGntc2VCeG:ydH;zbZMh[XO|YYm= MYWyJO69VQ>? NHnZeJgyOiCq Mke3TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDjbZNxdGG2aX6tdoV{cXO2YX70JIh2dWGwIFGyO|gxKGOnbHzzJIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIIDoc5NxcG:{eXzheIVlKEGtdDDs[ZZmdCCjdDCyJJVOKGGodHXyJFEzKGi{czDifUBqdW23bn;icI91KGGwYXz5d4l{Ng>? MnjMNVc3QDRyMUi=
human SW480 cells NUWwOYdDTnWwY4Tpc44h[XO|YYm= M1q4T|IxKM7:TR?= MYGyOEBp NX7ldIk4TGWlcnXhd4UhcW5ic4Xyeol3cW5iZYjwdoV{e2mxbjDpckBpfW2jbjDTW|Q5OCClZXzsd{BifCB{MDD1UUBi\nSncjCyOEBpenNiYomgbY1ufW6xYnzveEBidmGueYPpdy=> NHroTZEyPzR5Mkm2Ni=>
mouse mast cells MVfGeY5kfGmxbjDhd5NigQ>? MX6yNEDPxE1? MWLJcohq[mm2aX;uJI9nKFOFRj3pcoR2[2WmIGDLRk9Cc3RicHjvd5Bpd3K7bHH0bY9vKGmwIH3veZNmKG2jc4SgZ4VtdHNiYYSgNlAh|ryP MWqxOlc5QTd2Mh?=
human BJ cells NUXQXnBCTnWwY4Tpc44h[XO|YYm= NFHsbmwzPSEQvF2= NFz1SWMzKGh? MW\Jcohq[mm2aX;uJI9nKFCLM1ugd4lodmGuaX7nJIlvKFCGR1[td5RqdXWuYYTl[EB{\XK3bTDzeIFzfmWmIHj1cYFvKEKMIHPlcIx{KHS{YX7z[oVkfGWmIIfpeIgheGyjc33p[EBGT0[SL2DIJIRwdWGrbjDv[kBCc3RiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiUFitSWdHWCC{ZXTpd5RzcWK3dHnvckB1dyCybHHzcYEhdWWvYoLhcoUh[XRiMkWgeW0hfHKnYYTl[EAzKGi{czDi[YZwemViUFTHSkBkcGGubHXu[4Uh[nliY3;u[o9k[WxibXnjdo9{[2:yeR?= NUfncJhOOTZ5NkewPFU>
human IGROV1 cells MV;GeY5kfGmxbjDhd5NigQ>? NWGzNnhzOjRxNEigbC=> NUfNSW91UW6qaXLpeIlwdiCxZjDQTVNMN0GtdDDpckBpfW2jbjDJS3JQXjFiY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gdIhwe3Cqb4L5cIF1\WRiQVvUJIxmfmWuIHH0JFEhfG9iNTD0bY1meyCLQ{WwJIFnfGW{IEK0JJRwKDR6IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= M4jrTVIyOjF4MUWx
human IGROV1 cells MmruSpVv[3Srb36gZZN{[Xl? NIPW[4kzPC92ODDo M1zOSmlvcGmkaYTpc44hd2ZiUFmzT{9Cc3RiaX6gbJVu[W5iSVfSU3YyKGOnbHzzJIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIHP5Z4xqdiCGMTDs[ZZmdCCjdDCxJJRwKDVidHnt[ZMhUUN3MDDh[pRmeiB{NDD0c{A1QCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| MoDRNlEzOTZzNUG=
rat RBL2H3 cells MlLrSpVv[3Srb36gZZN{[Xl? Mn3nTY5pcWKrdHnvckBw\iCDMkOxPFcucW6mdXPl[EBl\We{YX71cIF1cW:wIHnuJJJifCCUQlyyTFMh[2WubIO= NX\iOFA2OTh|Mki3NVY>
human BJ cells M1K5WmZ2dmO2aX;uJIF{e2G7 NY[0fJlWOjVizszN MV:yJIg> MYTBZ5RqfmG2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25iYYSgWIhzOzB6IHnuJHBFT0Zvc4TpcZVt[XSnZDDz[ZJ2dSC|dHHyeoVlKGi3bXHuJGJLKGOnbHzzJIF1KDJ3IIXNJJRz\WG2ZXSgNkBpenNiYnXmc5JmKFCGR1[gZ4hidGynbnflJIJ6KGmvbYXuc4Jtd3S2aX7n NUTa[W9iOTZ5NkewPFU>
human HCT116 cells NVTFeI9TTnWwY4Tpc44h[XO|YYm= MVWxNEDPxE1? NVjZN4dEOTBibXnu NGfR[2RKdmirYnn0bY9vKG:oIGDJN2tidHCqYTDpckBpfW2jbjDIR3QyOTZiY3XscJMhfXOrbnegX|MzWF2DVGCgZZQhOTBidV2gZYZ1\XJiMUCgcYlvew>? MkPhNlIzOTJ5MkG=
human HCT116 cells NXPSOHJkTnWwY4Tpc44h[XO|YYm= NXPrZ283OTBizszN NWfUepAxOTBibXnu MWjJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCKMUC0O3IhdXW2YX70JIlvKGi3bXHuJGhEXDFzNjDj[YxteyC3c3nu[{BcOzKSXVHUVEBifCBzMDD1UUBi\nSncjCxNEBucW6| NXnjempVOjJ{MUK3NlE>
human HCT116 cells Mm\HSpVv[3Srb36gZZN{[Xl? NX7GXGF4OTBizszN NUXmU4pnUW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgbY4hcHWvYX6gTGNVOTF4IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhSWu2IGPldlQ4OyCyaH;zdIhwenmuYYTpc44h[XRiMUCgeW0h[nliaX3teY5w[myxdDDhcoFtgXOrcx?= M3jIV|IzOjF{N{Kx
human HCT116 cells MXrGeY5kfGmxbjDhd5NigQ>? M4fVdFExKM7:TR?= M4TCNmlvcGmkaYTpc44hd2ZiUFmzT4FteGijIFixNFQ4WiCvdYThcpQhcW5iaIXtZY4hUEOWMUG2JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiQXv0JHNmejR5MzDwbI9{eGixconsZZRqd25iYYSgNVAhfU1iYomgbY1ufW6xYnzveEBidmGueYPpdy=> NVj6dHJmOjJ{MUK3NlE>
human PC3 cells NEDyPXVHfW6ldHnvckBie3OjeR?= NVGyZZlQPTBizszN MmL6PEBp MnrQTY5lfWO2aX;uJI9nKHB{MTDwdo91\WmwIHX4dJJme3Orb36gbY4hcHWvYX6gVGM{KGOnbHzzJIF1KDVyIIXNJIlv[3WkYYTl[EBnd3JiODDodpMh[nliV3XzeIVzdiCkbH;0eIlv\yC{ZXzheIl3\SC2bzD1cpRz\WG2ZXSgZ49vfHKxbB?= NVTtZmNHOjJ7OUi0O|I>
human LNCAP cells NVjS[FFiTnWwY4Tpc44h[XO|YYm= M{DN[VAvOS1|MDFOwG0> M{DTbFMxKG2rbh?= NH:zbItKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gUG5ESVBiY3XscJMh[XRiMD6xJJRwKDNyIIXNJIFnfGW{IEOwJI1qdnNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ M3\T[lIzQDN{M{G2
human LNCAP cells M3r0T2Z2dmO2aX;uJIF{e2G7 MYCwMlEuOzBizszN M{TvZ|I1KGh? NH61SolFd3ewcnXneYxifGmxbjDv[kB{fXK4aY\pckBmgHC{ZYPzbY9vKGmwIHj1cYFvKEyQQ1HQJINmdGy|IHH0JFAvOSC2bzCzNEB2VSCjZoTldkAzPCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NWC3d25DOjJ6M{KzNVY>
HUVEC NHPmbZpHfW6ldHnvckBie3OjeR?= M1HNXlExNTJ3IN88US=> MVixOkBp M4fwbWlvcGmkaYTpc44hd2ZiVF7GZYxxcGFvc4TpcZVt[XSnZDDJR2FONTFibWLORUBmgHC{ZYPzbY9vKGmwIFjVWmVEKGG2IEGwJJRwKDJ3IIXNJJBz\XS{ZXH0[YQh\m:{IEG2JIhzeyCkZX\vdoUhXE6IYXzwbIEh[2ijbHzlcodmKG2nYYP1doVlKGGodHXyJFYhcHK|IHL5JHJVNVCFUjDhcoFtgXOrcx?= MmW1NlIxOjZ2MUC=
HUVEC MkPYSpVv[3Srb36gZZN{[Xl? M4HhXFExNTJ3IN88US=> MWKzNEBucW5? MXfJcohq[mm2aX;uJI9nKFSQRnHsdIhiNXO2aX31cIF1\WRiaIXtZY4hUUODTT2xJJBzd22xdHXyJIFkfGm4aYT5JIV5eHKnc4Pl[EBqdiCKVW\FR{Bie3Onc4Pl[EBieyCkZYThMYdidGGldH;zbYRie2ViYXP0bZZqfHliYYSgNVAhfG9iMkWgeW0heHKndILlZZRm\CCob4KgN|AhdWmwczDi[YZwemViVF7GZYxxcGFiY3jhcIxmdmenIH3lZZN2emWmIHHmeIVzKDViaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeR?= NVn5TI44OjJyMk[0NVA>
human H1299 cells MlrNSpVv[3Srb36gZZN{[Xl? NVjjfFlHOC5zLUOwJO69VQ>? M1GyV|I1KGh? NX7iNXhHTG:5bjDy[Yd2dGG2aX;uJI9nKGOLQWCyJIV5eHKnc4Ppc44hcW5iaIXtZY4hUDF{OUmgZ4VtdHNiYYSgNE4yKHSxIEOwJJVOKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? M1\JdFIzPjJ{ME[5
human H1299 cells MlrHSpVv[3Srb36gZZN{[Xl? MmrvNE4yNTNyIN88US=> MUKyOEBp M4PtcmRwf25icnXneYxifGmxbjDv[kBkUUGSMjDlfJBz\XO|aX;uJIlvKGi3bXHuJGgyOjl7IHPlcIx{KGG2IECuNUB1dyB|MDD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{KGmwIIDy[ZNmdmOnIH;mJFExOCC3Zz;tcEBVWkGLTDDhcoQhWEl|SzDpcohq[mm2b4KgUHkzQTRyMEK= NUKz[HJTOjJ4MkKwOlk>
human H1299 cells Mn7LSpVv[3Srb36gZZN{[Xl? NVT2SFM1OC5zLUOwJO69VQ>? MmXGNlQhcA>? NWHMSmh6UW6mdXP0bY9vKG:oIFTSOUBmgHC{ZYPzbY9vKGmwIHj1cYFvKEhzMkm5JINmdGy|IHH0JFAvOSC2bzCzNEB2VSCjZoTldkAzPCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NU\CVWtVOjJ4MkKwOlk>
human H1299 cells NGCzWHdHfW6ldHnvckBie3OjeR?= MXywMlEuOzBizszN MofiNlQhcA>? NXS4PYhwUW6mdXP0bY9vKG:oIFrOT{1u\WSrYYTl[EBEUE:SIHX4dJJme3Orb36gbY4hcHWvYX6gTFEzQTliY3XscJMh[XRiMD6xJJRwKDNyIIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> MU[yNlYzOjB4OR?=
HEK293 cells NHrJdpVHfW6ldHnvckBie3OjeR?= NEXWRlAyNjViaB?= Mn3lSIl{eGyjY3Xt[Y51KG:oIGuzTH1NW0RiZoLvcUBpfW2jbjC1THQ3KHKnY3XweI9zKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[W[2ZYKgNU42KGi{czDifUBtcXG3aXSgd4NqdnSrbHzheIlwdiClb4XueIlv\w>? MkDjNlI2OzdzNUO=
human U251HRE cells NY\LSWY1TnWwY4Tpc44h[XO|YYm= NHHGfY5KdmirYnn0bY9vKG:oIHj5dI95cWFvaX7keYNm\CCKSV[xJIFkfGm4YYTpc44hcW5iaIXtZY4hXTJ3MVjSSUBk\WyuczDifUBk\WyuIHLhd4VlKHKncH;yeIVzKGenbnWgZZN{[Xl? NUjze3B5OTh3MEG2NFE>
human HCT116 cells MoDnSpVv[3Srb36gZZN{[Xl? NHvoem4yOCEQvF2= NWnZfpZtUW6qaXLpeIlwdiCxZjDBb5Qh\XiycnXzd4lwdiCrbjDoeY1idiCKQ2SxNVYh[2WubIOgZZQhOTBidV2gZpkhcW2vdX7vZoxwfCCjbnHsfZNqew>? MV[yNlIyOjd{MR?=
Sf9 cells MUDmcJVwemW|Y3XueEBxd2yjcnn6ZZRqd25iYYPzZZk> MWLJcohq[mm2aX;uJI9nKGi3bXHuJHBKO0upYX3tZUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy|IHL5JIZtfW:{ZYPj[Y51KHCxbHHybZpifGmxbjDhd5NigQ>? NYjWPZZ4OjFzMkG2N|E>
human HCT116 cells NG\WeHpRem:uaX\ldoF1cW:wIHHzd4F6 NFHWOXI4OiCq MX3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHid49z[mGwY3WgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD13MT64NkDPxE1w M2HVdlI2Pjl|N{i3
human HCT116 cells NIji[JpEgXSxdH;4bYPDqGG|c3H5 NWK4UItjPzJiaB?= MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME21Ok4xOSEQvF2u NEP6cFEzOTl2NUK1NC=>
human PC3 cells NWW2S21qS3m2b4TvfIlkyqCjc4PhfS=> MVm3NkBp Mmm1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NkGuN|Uh|ryPLh?= MUmyNlQ5ODh3MR?=
human HuH7 cells NVf3eGFyWHKxbHnm[ZJifGmxbjDhd5NigQ>? MV:3NkBp MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEi3SEegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCjYoPvdoJidmOnIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PjdwMUig{txONg>? MorKNlU3QTN5OEe=
human A549 cells NYnOOWdMWHKxbHnm[ZJifGmxbjDhd5NigQ>? MV63NkBp M{nwVmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHid49z[mGwY3WgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD16Mj6zNkDPxE1w MWiyOVY6Ozd6Nx?=
human A549 cells NIrY[21EgXSxdH;4bYPDqGG|c3H5 NXe1WmtmPzJiaB?= NVHyZVRsS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6 M{LzcVIzPDhyOEWx
human PC3 cells NEPuXHVRem:uaX\ldoF1cW:wIHHzd4F6 MV2yOUDPxE1? NXjX[|ZOOTJyIHi= NXXSdVFwSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOgZZQhOjVidV2gZYZ1\XJiMUKwJIhzeyCkeTDNWHQh[XO|YYmgdoVt[XSrdnWgeI8hTE2VTx?= MWGxOlY5ODF3OR?=
human H460 cells MoLvSpVv[3Srb36gZZN{[Xl? MoXzN|Ah|ryP MW\Jcohq[mm2aX;uJI9nKFCLM1ugbY4hcHWvYX6gTFQ3OCClZXzsd{Bie3Onc4Pl[EBieyCDa4SgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmeiB2N{OgeZAhfG9iM{CgeW0> NF\OV|cyQDVyMU[wNS=>
human IGROV1 cells MYfGeY5kfGmxbjDhd5NigQ>? NIPIdXEzPCCq NHrpSVVE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBKT1KRVkGgZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IFexJJBp[XOnIHH0JFEh\m:uZDDJR|UxKGGodHXyJFI1KGi{czDifUBndG:5IHP5eI9u\XS{eR?= MoTnNlEzOTZzNUG=
human IGROV1 cells MnvRSpVv[3Srb36gZZN{[Xl? NGrYeGwzPCCq Mn7QR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gTWdTV1ZzIHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBifCCJMTDwbIF{\SCjdDC1JIZwdGRiSVO1NEBi\nSncjCyOEBpenNiYomg[oxwfyCleYTvcYV1enl? MYWyNVIyPjF3MR?=
human H4 cells M{C5c2Z2dmO2aX;uJIF{e2G7 M4nMclIhcA>? MX\E[YNz\WG|ZTDpckBHYV[HLWLGVEshfmW|aXPs[UBqdnSnboPpeJkheGW{IHPlcIwhcW5iaIXtZY4hUDRiY3XscJMh[W[2ZYKgNkBpenNicnXsZZRqfmVidH:gZ49vfHKxbB?= Mn3XNVgxOjR3OES=
human MGC803 cells NF;TUY9HfW6ldHnvckBie3OjeR?= MnnqNlUh|ryP Mo\OOFghcA>? MVLD[YxtKGO7Y3zlJIFzemW|dDDpckBpfW2jbjDNS2M5ODNiY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEd{L12gdIhie2ViYYSgNlUhfU1iYX\0[ZIhPDhiaILzJJV{cW6pIIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYX\0[ZIhPDhiaILzJIJ6KG[ub4egZ5l1d22ndHXyJJJmdGG2aY\lJJRwKGOxboTyc4w> NGniO5QzPDFzOUi2PS=>

... Click to View More Cell Line Experimental Data

In vivo LY294002 also results in suppression of tumor growth and induction of apoptosis, especially in the LoVo tumors, and therefore shows remarkable effectiveness in the mouse peritonitis carcinomatosa model. [2] LY294002 significantly inhibits growth and ascites formation of ovarian carcinoma. [3]

Protocol

Kinase Assay:

[4]

+ Expand

kinase assays:

PI3K inhibition by LY294002 is determined in a radiometric assay using purified, recombinant enzymes with 1 μM ATP. The kinase reaction is carried out for 1 hour at room temperature (24oC) and is terminated by addition of PBS. IC50 values are subsequently determined using a sigmoidal dose–response curve fit (variable slope). CK2 and GSK3β (glycogen synthase kinase 3β) inhibition is established by kinase selectivity screening. LY294002 is tested against the Upstate panel of kinases in 10 μM ATP.
Cell Research:

[2]

+ Expand
  • Cell lines: Colon cancer cell lines DLD-1, LoVo, HCT15, and Colo205
  • Concentrations: 0–50 μM
  • Incubation Time: 0–48 hours
  • Method:

    1.0×105 cells (100 μL volume/well) are inoculated into 96-well microtiter plates. LY294002 is added to triplicate wells and cultured at 37oC for 0–48 hours. After treatment, 10 μL of Premix WST-1 are added to each microculture well, and the plates are incubated for 60 minutes at 37oC, after which absorbance at 450 nm is measured with a microplate reader.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Two groups of athymic nude mice (5–7 weeks) are inoculated i.p. with OVCAR-3 cells
  • Formulation: Dissolved in DMSO plus 0.25 ml of PBS
  • Dosages: 0–100 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 36 mg/mL (117.13 mM)
Ethanol 21 mg/mL (68.32 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 307.34
Formula

C19H17NO3

CAS No. 154447-36-6
Storage powder
in solvent
Synonyms SF 1101, NSC 697286

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to buy a inhibitor that can inactivates Akt/PI3K. I notice the protocol of LY294002 (catalog no. s1105) says it will inactivates Akt/PKB. Is LY294002 available for Akt/PI3K inhibition?

  • Answer:

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively. It can inhibit PI3K/AKT. PKB is the alternative name of AKT.

  • Question 2:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • Answer:

    It can be dissolved in 4% DMSO/30% PEG 300/5% Tween 80/ddH2O at 5 mg/ml clearly, and the concentration of DMSO is safe for in vivo experiments.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy LY294002 | LY294002 supplier | purchase LY294002 | LY294002 cost | LY294002 manufacturer | order LY294002 | LY294002 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID